-
1.发明公开
公开(公告)号：EP4400113A1
公开(公告)日：2024-07-17
申请号：EP21953423.7
申请日：2021-12-27
发明人： XU, Jianqing , ZHANG, Xiaoyan , LIAO, Qibin , DING, Xiangqing
IPC分类号： A61K38/00 , A61K48/00 , A61K45/00 , C12N15/867 , C12N5/10
CPC分类号： Y02A50/30
摘要： The present invention provides a hypoxia-triggered artificial transcription factor (HATF), and further provides a hypoxia-triggered transcription control system. The transcription control system comprises a nucleic acid sequence encoding the HATF, and a recognition element (RE). The hypoxia-triggered transcription control system comprises two sets of transcription control units linked upstream and downstream, wherein the upstream transcription control unit comprises a hypoxia-triggered transcription reaction element for controlling the HATF and a nucleic acid sequence encoding the HATF, and the downstream transcription control unit comprises an RE and a gene of interest. Co-regulation by the artificial transcription factor HATF and the recognition element RE can increase the expression of the gene of interest by a factor of one hundred.
-
2.发明公开
公开(公告)号：EP4357365A1
公开(公告)日：2024-04-24
申请号：EP21945436.0
申请日：2021-06-16
发明人： XU, Jianqing , ZHANG, Xiaoyan , DING, Xiangqing , LIAO, Qibin
IPC分类号： C07K16/40 , A61K39/395 , C12N5/10 , C12N15/13 , C12N15/63 , A61P35/00 , A61K45/00 , A61K35/17
CPC分类号： A61K35/17 , A61K39/395 , A61K45/00 , A61P35/00 , C07K16/00 , C07K16/40 , C12N5/10 , C12N15/63
摘要： The present invention provides an antibody targeting an AXL protein or an antigen binding fragment thereof, and a preparation method therefor and use thereof. Further provided are an isolated polynucleotide encoding the antibody targeting the AXL protein or the antigen binding fragment thereof, and a vector comprising the isolated polynucleotide. The antibody targeting the AXL provided by the present invention can specifically bind to the AXL protein, can mediate ADCC to kill tumors, or have an anti-tumor effect as a target recognition domain of CART cells, and can be used for preventing or treating tumors, and hence it has a wide application prospect.
-
3.发明公开
公开(公告)号：EP4424714A1
公开(公告)日：2024-09-04
申请号：EP21961885.7
申请日：2021-10-29
发明人： XU, Jianqing , ZHANG, Xiaoyan , LIAO, Qibin , DING, Xiangqing , WANG, Shiyu
摘要： A condition-controlled spliceable chimeric antigen receptor molecule and the use thereof. The spliceable chimeric antigen receptor molecule comprises an antigen recognition unit and a signal transduction unit; the antigen recognition unit comprises an antigen recognition domain, a transmembrane domain, a costimulatory signal domain, an N-terminal splicing domain, and a degrader; and the signal transduction unit comprises a conditional signal response domain, a C-terminal splicing domain, and a signaling domain. Such a condition-controlled spliceable system can achieve splicing of the two units and signaling under a tumor microenvironment signal. The antigen recognition unit can spontaneously/be induced to degrade, thus reducing retention in normal tissues. A signaling unit can respond to a specific condition signal of a tumor microenvironment, and has the characteristics of low expression in a normal tissue environment and high expression in the tumor microenvironment. The condition-controlled spliceable system can achieve preparation of drugs and precise treatment for solid tumors by grafting different functional genes.
-
4.发明公开
公开(公告)号：EP4393955A1
公开(公告)日：2024-07-03
申请号：EP22860533.3
申请日：2022-08-24
发明人： XU, Jianqing , ZHANG, Xiaoyan , DING, Xiangqing , LIAO, Qibin , ZHANG, Dan
IPC分类号： C07K16/30 , C07K16/46 , C07K19/00 , C12N15/13 , C12N15/64 , C12N15/85 , C12N15/86 , C12N15/863 , A61K39/395 , A61P35/00
CPC分类号： A61K39/395 , A61P35/00 , C07K16/00 , C07K16/30 , C07K16/46 , C07K19/00 , C12N15/64 , C12N15/85 , C12N15/863 , C12N15/86
摘要： Provided is an antibody capable of specifically binding to CD47 or an antigen binding fragment thereof. Also provided is a recombinant oncolytic virus, which is operably inserted with or comprises a gene coding sequence of an anti-CD47 antibody or a CD47 ligand, wherein the anti-CD47 antibody comprises an Fc mutant having A330L/I332E mutations (ALIE antibody), i.e., the anti-CD47 antibody is αCD47-Fc(ALIE).Also provided are a preparation method for the recombinant oncolytic virus, a use of the recombinant oncolytic virus in preparation of anti-tumor drugs, and a vaccinia virus Tiantan strain capable of efficiently expressing an αCD47-Fc(ALIE) gene.
-
公开(公告)号：EP4458862A1
公开(公告)日：2024-11-06
申请号：EP21969269.6
申请日：2021-12-27
发明人： XU, Jianqing , ZHANG, Xiaoyan , DING, Xiangqing , LIAO, Qibin , WANG, Shiyu , ZHOU, Junhua
IPC分类号： C07K19/00 , C12N7/01 , C12N15/62 , C12N15/863 , A61K35/76 , A61K35/768 , A61K39/395 , A61P35/00
摘要： Provided by the present invention are a bispecific T-cell engager, recombinant oncolytic virus thereof, and use thereof. The present invention provides an αCD47 and αCD3 bispecific T-cell engager. The present invention also provides an isolated nucleic acid molecule that encodes said bispecific T-cell engager. The present invention also provides an expression framework of said bispecific T-cell engager BiTE. The present invention also provides a recombinant oncolytic virus, and said oncolytic virus is operably inserted with or contains the expression framework of said bispecific T-cell engager BiTE. In the present invention, the bispecific T-cell engager is combined with the oncolytic virus, and in comparison with pure gene therapy or virotherapy, the oncolytic virus significantly enhances the inhibition capability on malignant tumors.
-
公开(公告)号：EP3936611A1
公开(公告)日：2022-01-12
申请号：EP19917821.1
申请日：2019-03-05
发明人： XU, Jianqing , ZHANG, Xiaoyan , LIAO, Qibin
IPC分类号： C12N5/0783 , A61K35/17 , A61P35/00
摘要： A composition for inducing and/or amplifying T SCM in vitro, a culture medium including the composition, and a method for inducing and/or amplifying T SCM in vitro are provided, wherein the composition comprises inducing agents including IL-7 and IL-21. The chimeric antigen receptor T-memory stem cells induced differentiated and amplified by adding the composition can be used directly for reinfusion therapy of patients.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.011 秒)
